Jardine Matheson Holdings Ltd. is nearing a deal to buy I-MED Radiology Network Ltd., a move that would integrate Australia’s largest medical diagnostic imaging provider into its portfolio, according to people familiar with the talks. The acquisition, valued at approximately $2.4 billion, positions Jardine to expand its healthcare footprint in a sector driven by aging populations and rising demand for diagnostic services. While details remain confidential, the deal is expected to close by mid-2024, pending regulatory approvals. This strategic step aligns with Jardine’s broader push into high-margin healthcare services, leveraging I-MED’s established network of imaging centers and partnerships with hospitals across Australia. The transaction underscores growing consolidation in the global medical imaging industry, where larger players seek scale to compete with tech-driven startups and telehealth platforms.

The acquisition builds on Jardine’s existing healthcare investments, including its stakes in Singapore-based Parkway Pantai and Hong Kong’s Xinhua Hospital. By adding I-MED, Jardine gains access to advanced imaging technologies and a robust referral network from general practitioners, which could enhance revenue streams through bundled service offerings. For I-MED, the deal offers financial stability amid sectoral challenges like reimbursement pressures and staffing shortages. However, the merger may face scrutiny over market dominance, particularly in regions where I-MED already holds significant market share.

Regulatory hurdles remain a key risk, as antitrust authorities could block the deal if it reduces competition in local markets. Analysts note that Jardine’s history of navigating complex approvals—seen in its past healthcare acquisitions—suggests a proactive approach to compliance. The $2.4 billion valuation reflects I-MED’s profitability and growth potential, though the final price could adjust based on negotiations over liabilities or asset valuations. This deal highlights the sector’s attractiveness, with healthcare mergers and acquisitions surging 18% globally in 2023, per industry reports. Investors may monitor how the move impacts Jardine’s balance sheet, given its existing debt load from prior expansions.

The $2.4 billion acquisition marks a pivotal moment for both firms. For Jardine, it signals a commitment to deepening its healthcare verticals beyond traditional pharmaceutical and insurance businesses. For I-MED, the partnership could unlock resources to invest in AI-driven diagnostics and patient management systems. While the deal’s success hinges on seamless integration, the combination of Jardine’s financial muscle and I-MED’s clinical expertise positions them to capture a larger share of Australia’s $12 billion medical imaging market. This transaction exemplifies how legacy conglomerates are pivoting to healthcare to offset slowing growth in core sectors like retail and property.